Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 567

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 567
---
plAI Health Ltd. mutually agreed to terminate the Amended and Restated Share Purchase Agreement (SPA) originally executed on March 13, 2024, effectively ending MultiplAI Health Ltd.’s participation in the BCA. Despite this development, the transaction remains and is supported by other key agreements, including a Voting and Support Agreement and a Backstop Agreement to ensure the business combination fees are covered, along with compliance with U.S. securities regulations and Nasdaq listing standards. This combination establishes OmnigenicsAI as a combined entity leveraging integrated genomic and AI -drivenhealth solutions. The Group conducts its business operations through two business segments, Heritas Diagnostics and Rewell. The Heritas Diagnostics segment provides a suite of clinical genetic tests for doctors, patients, and their families, for diagnosis, prognosis and monitoring, allowing them to make informed decisions over various conditions. These tests are distributed through exclusive partnerships with clinical laboratories, empowering them to offer these advanced diagnostic services to their customers. Heritas Diagnostics products are used for reproductive genetics, oncology, genetic and rare diseases, and human microbiome testing purposes. The Rewell segment provides customers with direct access to DNA and microbiome information to enable them to make more informed long -termhealth decisions and minimize the development of chronic diseases. This includes providing F-69 Notes to Combined Financial Statements (Amounts in US Dollars, except otherwise indicated) 1.The Group’s business, reorganization and general information (cont.) health risk information through Polygenic Risk Scores (“PRS”). Customers view their results on Rewell’s proprietary digital platform, where consumers can also schedule a telemedicine consultation with a healthcare professional to interpret their results and receive a health plan with recommendations. Basis of presentation and consolidation The accompanying financial statements include the combined financial results for Omnigenics and Heritas Argentina for the fiscal years ended June 30, 2024, and June 30, 2023. The financial statements for the fiscal year ended June 30, 2023, reflect the operations of Heritas Argentina prior to its acquisition by Omnigenics. The financial statements for the fiscal year ended June 30, 2024, reflect the combined operations of Omnigenics and its wholly owned subsidiary, Heritas Argentina, following the reorganization. The financial statements have been prepared using consistent accounting policies across both fiscal years to ensure comparability. The reorganization on February 26, 2024, represents a combination of entities under common control. This transaction does not meet the definition of a business combination